Studies have found that changes in serum tryptophan are closely related to disease progression, with the progression of RA leading to decreased tryptophan levels due to IDO1-induced tryptophan degradation (51), providing important theoretical basis for identifying diagnostic and therapeutic biomarkers for RA. The gene discussed is IDO1; the disease is rheumatoid arthritis.